April 10, 2017
Kyowa Hakko Kirin said on April 7 that its humanized monoclonal antibody mogamulizumab met the primary endpoint in a global PIII study for cutaneous T-cell lymphoma (CTCL) by significantly improving progression free survival (PFS) versus an active control drug. The...read more